Judong Lee

Judong Lee

Auto-generated profile, based on publicly available information

Judong Lee

Emory Vaccine Center, Emory University School of Medicine, Atlanta, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MHMasao Hashimoto
Masao Hashimoto
KAKoichi Araki
Koichi Araki
MCMaria A. Cardenas
Maria A. Cardenas
PLPeng Li
Peng Li
RJRohit Jadhav
Rohit Jadhav
RARafi Ahmed
Rafi Ahmed

4 August 2023 in Science Immunology
Verified
Journal Article
Closed access
AGAmanda L. Gill
Amanda L. Gill
PWPeter H. Wang
Peter H. Wang
JLJudong Lee
Judong Lee
WHWilliam H. Hudson
William H. Hudson
SASatomi Ando
Satomi Ando
RARafi Ahmed
Rafi Ahmed
PD-1 + TCF-1 + stem-like CD8 T cells act as critical resource cells for maintaining T cell immunity in chronic viral infections and cancer. In addition, they provide the proliferative burst of effector CD8 T cells after programmed death protein 1 (PD-1)–directed immunotherapy. However, it is not known whether checkpoint blockade diminishes the number of these stem-like progenitor cells as effector cell differentiation increases. To investigate this, we used the mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection. Treatment of chronically infected mice with either αPD-1 or αPD-L1 antibody not only increased effector cell differentiation from the virus-specific stem-like CD8 T cells but also increased their proliferation so their numbers were maintained. The increased self-renewal of LCMV-specific stem-like CD8 T cells was mTOR dependent. We used microscopy to understand the division of these progenitor cells and found that after PD-1 blockade, an individual dividing cell could give rise to a differentiated TCF-1 − daughter cell alongside a self-renewing TCF-1 + sister cell. This asymmetric division helped to preserve the number of stem-like cells. Moreover, we found that the PD-1 + TCF-1 + stem-like CD8 T cells retained their transcriptional program and their in vivo functionality in terms of responding to viral infection and to repeat PD-1 blockade. Together, our results demonstrate that PD-1 blockade does not deplete the stem-like population despite increasing effector differentiation. These findings have implications for PD-1–directed immunotherapy in humans.

8 January 2025 in Nature
Verified
Journal Article
Closed access
PDF file
DMDaniel T. McManus
Daniel T. McManus
RVRajesh M. Valanparambil
Rajesh M. Valanparambil
CMChristopher B. Medina
Christopher B. Medina
CSChristopher Scharer
Christopher Scharer
DMDonald J. McGuire
Donald J. McGuire
RARafi Ahmed
Rafi Ahmed

22 November 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AMAnnapaola Mariniello
Annapaola Mariniello
TNTahseen Nasti
Tahseen Nasti
DCDaniel Y. Chang
Daniel Y. Chang
MHMasao Hashimoto
Masao Hashimoto
SMSakshi Malik
Sakshi Malik
RARafi Ahmed
Rafi Ahmed
Purpose: Combination of chemotherapy with programmed cell death 1 (PD-1) blockade is a front-line treatment for lung cancer. However, it remains unknown whether and how chemotherapy affects the response of exhausted CD8 T cells to PD-1 blockade. Experimental Design: We used the well-established mouse model of T-cell exhaustion with chronic lymphocytic choriomeningitis virus (LCMV) infection to assess the effect of chemotherapy (cisplatin+pemetrexed) on T-cell response to PD-1 blockade, in the absence of the impact of chemotherapy on antigen release and presentation observed in tumor models. Results: When concomitantly administered with PD-1 blockade, chemotherapy affected the differentiation path of LCMV-specific CD8 T cells from stem-like to transitory effector cells, thereby reducing their expansion and production of IFNγ. After combination treatment, these restrained effector responses resulted in impaired viral control, compared with PD-1 blockade alone. The sequential combination strategy, where PD-1 blockade followed chemotherapy, proved to be superior to the concomitant combination, preserving the proliferative response of exhausted CD8 T cells to PD-1 blockade. Our findings suggest that the stem-like CD8 T cells themselves are relatively unaffected by chemotherapy partly because they are quiescent and maintained by slow self-renewal at the steady state. However, upon the proliferative burst mediated by PD-1 blockade, the accelerated differentiation and self-renewal of stem-like cells may be curbed by concomitant chemotherapy, ultimately resulting in impaired overall CD8 T-cell effector functions. Conclusions: In a translational context, we provide a proof-of-concept to consider optimizing the timing of chemo-immunotherapy strategies for improved CD8 T-cell functions. See related commentary by Vignali and Luke, p. 1705

25 March 2026 in Nature
Verified
Journal Article
Closed access
PDF file
CMChristopher B. Medina
Christopher B. Medina
ESEwelina Sobierajska
Ewelina Sobierajska
MGMinghao Gong
Minghao Gong
DMDaniel T. McManus
Daniel T. McManus
MTMaheshwor Thapa
Maheshwor Thapa
RARafi Ahmed
Rafi Ahmed

1 May 2024
Verified
Other
Open access
AMAnnapaola Mariniello
Annapaola Mariniello
TNTahseen Nasti
Tahseen Nasti
DCDaniel Y. Chang
Daniel Y. Chang
MHMasao Hashimoto
Masao Hashimoto
SMSakshi Malik
Sakshi Malik
RARafi Ahmed
Rafi Ahmed
(A) Number of total lymphocytes, CD8 and CD4 T cells in the spleen across the treatment groups. (B-C) Frequency of PD-1+ and LCMV-specific CD8 T cells in the spleen and in the lung. Data are pooled from 2-3 experiments of 4-5 mice per group. For statistical analysis, the one-way ANOVA test was used; total numbers were Log10 transformed. Bars represent mean and SEM. *p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001.